A 52-Week Placebo-Controlled Trial of Evolocumab in Hyperlipidemia — NEJM

Retweeted NEJM (@NEJM): A 52-Week Placebo-Controlled Trial of Evolocumab in Hyperlipidemia http://t.co/S3vjF3a1Oj

via VAT ENGPlus Combo | VATPlus | MotionTrak http://t.co/S3vjF3a1Oj